{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:35:08Z","timestamp":1768970108992,"version":"3.49.0"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Penn State Health No Shave November Education and Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: MRI fusion prostate biopsy has improved the detection of clinically significant prostate cancer (CSC). Continued refinements in predicting the pre-biopsy probability of CSC are essential for optimal patient counseling. We investigated potential factors related to improved cancer detection rates (CDR) of CSC in patients with PI-RADS \u2265 3 lesions. Methods: The pathology of 980 index lesions in 980 patients sampled by transrectal mpMRI-targeted prostate biopsy across four medical centers between 2017\u20132020 was reviewed. PI-RADS lesion distribution included 291 PI-RADS-5, 374 PI-RADS-4, and 315 PI-RADS-3. We compared CDR of index PI-RADS \u2265 3 lesions based on location (TZ) vs. (PZ), PSA density (PSAD), and history of prior negative conventional transrectal ultrasound-guided biopsy (TRUS). Results: Mean age, PSA, prostate volume, and level of prior negative TRUS biopsy were 66 years (43\u201390), 7.82 ng\/dL (5.6\u201311.2), 54 cm3 (12\u2013173), and 456\/980 (46.5%), respectively. Higher PSAD, no prior history of negative TRUS biopsy, and PZ lesions were associated with higher CDR. Stratified CDR highlighted significant variance across subgroups. CDR for a PI-RADS-5 score, PZ lesion with PSAD \u2265 0.15, and prior negative biopsy was 77%. Conversely, the CDR rate for a PI-RADS-4 score, TZ lesion with PSAD &lt; 0.15, and prior negative biopsy was significantly lower at 14%. Conclusions: For index PI-RADS \u2265 3 lesions, CDR varied significantly based on location, prior history of negative TRUS biopsy, and PSAD. Such considerations are critical when counseling on the merits and potential yield of prostate needle biopsy.<\/jats:p>","DOI":"10.3390\/curroncol31080329","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:24:16Z","timestamp":1722957856000},"page":"4406-4413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions"],"prefix":"10.3390","volume":"31","author":[{"given":"Ahmad N.","family":"Alzubaidi","sequence":"first","affiliation":[{"name":"Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Zheng","sequence":"additional","affiliation":[{"name":"Pennsylvania State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Said","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanjia","family":"Fan","sequence":"additional","affiliation":[{"name":"Pennsylvania State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maidaa","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Florida College of Medicine, Gainesville, FL 32611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Grant","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-576X","authenticated-orcid":false,"given":"Max","family":"Yudovich","sequence":"additional","affiliation":[{"name":"Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraj","family":"Pursnani","sequence":"additional","affiliation":[{"name":"Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"Owens","sequence":"additional","affiliation":[{"name":"UPMC Central PA Hospital, Camphill, PA 17011, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stringer","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Florida College of Medicine, Gainesville, FL 32611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad R.","family":"Tracy","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[{"name":"Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.euo.2021.03.004","article-title":"Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study","volume":"5","author":"Ahdoot","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.eururo.2016.08.004","article-title":"Complications After Systematic, Random, and Image-guided Prostate Biopsy","volume":"71","author":"Borghesi","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"djw039","DOI":"10.1093\/jnci\/djw039","article-title":"Efficiency of Prostate Cancer Diagnosis by MR\/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions","volume":"108","author":"Siddiqui","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1007\/s00330-015-4015-6","article-title":"Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: Critical evaluation using whole-mount pathology as standard of reference","volume":"26","author":"Vargas","year":"2016","journal-title":"Eur. Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_11","unstructured":"(2023, October 16). Available online: https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/PI-RADS\/PIRADS-V2-1."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cct.2015.02.008","article-title":"PROMIS\u2014Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer","volume":"42","author":"Parker","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.euo.2020.02.005","article-title":"Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review","volume":"3","author":"Stabile","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193.e1","DOI":"10.1016\/j.urolonc.2020.09.019","article-title":"Optimizing MRI-targeted prostate biopsy: The diagnostic benefit of additional targeted biopsy cores","volume":"39","author":"Tracy","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Natale, C., Koller, C.R., Greenberg, J.W., Pincus, J., and Krane, L.S. (2021). Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions. Life, 11.","DOI":"10.3390\/life11121432"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109071","DOI":"10.1016\/j.ejrad.2020.109071","article-title":"Optimizing size thresholds for detection of clinically significant prostate cancer on MRI: Peripheral zone cancers are smaller and more predictable than transition zone tumors","volume":"129","author":"Mahjoub","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00330-020-06773-1","article-title":"Validation of the PI-RADS language: Predictive values of PI-RADS lexicon descriptors for detection of prostate cancer","volume":"30","author":"Rudolph","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1148\/radiol.2020190646","article-title":"Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel","volume":"296","author":"Westphalen","year":"2020","journal-title":"Radiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euf.2018.02.012","article-title":"Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review","volume":"5","author":"Giganti","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235.e1","DOI":"10.1016\/j.urolonc.2020.12.015","article-title":"Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?","volume":"39","author":"Drobish","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000365697","article-title":"mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer\u2014A Retrospective Review of 92 Biopsied PIRADS 3 Lesions","volume":"8","author":"Liddell","year":"2015","journal-title":"Curr. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.juro.2006.09.039","article-title":"Prostate specific antigen density correlates with features of prostate cancer aggressiveness","volume":"177","author":"Kundu","year":"2007","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","article-title":"The Value of PSA Density in Combination with PI-RADS\u2122 for the Accuracy of Prostate Cancer Prediction","volume":"198","author":"Distler","year":"2017","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, Z.B., Wei, C.G., Zhang, Y.Y., Pan, P., Dai, G.-C., Tu, J., and Shen, J.-K. (2021). The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20\u2009ng\/mL. Biomed. Res. Int., 2021.","DOI":"10.1155\/2021\/3995789"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejrad.2018.05.004","article-title":"PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy na\u00efve patient population","volume":"104","author":"Cuocolo","year":"2018","journal-title":"Eur. J. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wen, J., Tang, T., Ji, Y., and Zhang, Y. (2022). PI-RADS v2.1 Combined with Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.861928"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12957-023-02959-1","article-title":"Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI","volume":"21","author":"Ma","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41391-023-00660-8","article-title":"Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy na\u00efve men","volume":"26","author":"Siddiqui","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1148\/radiol.2015142818","article-title":"Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging","volume":"277","author":"Muller","year":"2015","journal-title":"Radiology"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:54Z","timestamp":1760110074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["curroncol31080329"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31080329","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}